← Leaderboards
Ofer Reizes
Cleveland Clinic Lerner Com-Cwru
$1,352,690
Attributed
$1,542,296
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $322.9K · FY2015–22$500K$375K$250K$125K$0
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$1,542,296 · 3
By mechanism
R21$789,421 · 2
P01$752,875 · 1
Top collaborators
- Justin D. Lathia2 shared
Most similar at Cleveland Clinic Lerner Com-Cwru
Same institution · by research overlap
- Serpil C. Erzurum$45,061,611
- Mark E Lauer$2,466,532
- Eugene Blackstone$4,436,208
- Kurt P Spindler$17,863,867
- Alan Marc Gillinov$4,169,833
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseTranslatingPathway InteractionsInhibitor/AntagonistComplementLaboratoriesInnovationSuccessDrug DevelopmentDiagnosticDiagnostic TestsBackDrug DiscoveryDietCollaborationsCessation Of LifeCommercializationCancer EtiologyAsthmatic PatientCellsClinicClinical DataBronchodilator AgentsAsthma
Grant awards (9)
Hyperthermic Intraperitoneal Chemotherapy Mechanisms in Epithelial Ovarian Cancer$184,406
R21 · FY2022 · CA · contact PI
Hyperthermic Intraperitoneal Chemotherapy Mechanisms in Epithelial Ovarian Cancer$225,803
R21 · FY2021 · CA · contact PI
Core B: Technology Development and Commercialization$150,575
P01 · FY2020 · HL · contact PI
Core B: Technology Development and Commercialization$150,575
P01 · FY2019 · HL · contact PI
Core B: Technology Development and Commercialization$150,575
P01 · FY2018 · HL · contact PI
Core B: Technology Development and Commercialization$150,575
P01 · FY2017 · HL · contact PI
Cell-cell communication in CSC self renewal and breast cancer progression$172,369
R21 · FY2016 · CA · contact PI
Core B: Technology Development and Commercialization$150,575
P01 · FY2016 · HL · contact PI
Cell-cell communication in CSC self renewal and breast cancer progression$206,843
R21 · FY2015 · CA · contact PI